Clinical Research
Lilly Reports Phase 3 Retatrutide Results Against Semaglutide in Type 2 Diabetes
Eli Lilly says its investigational weekly retatrutide reduced A1c and body weight more than semaglutide 2 mg in an 80-week, open-label Phase 3 trial. Full results are not yet peer-reviewed, and retatrutide is not approved for routine use.
Nov 3, 2026 · 4 min read Read briefingPhoto by pharmasist.ca